Health & Pharm General

Queensland Bauxite Ltd (ASX:QBL) Unique Variations and High Levels of Cannabinoids Identified

🕔9/19/2017 9:40:42 AM

Queensland Bauxite Limited (ASX:QBL) is pleased to announce preliminary findings in relation to cannabinoid testing performed by its subsidiary Medical Cannabis Limited of some of MCL's low THC Cannabis cultivars. (THC is tetrahydrocannabinol Delta 9, a medical compound produced by Cannabis plants).

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Pork CRC Options Extended by 12 Months

🕔9/13/2017 9:36:01 AM

Anatara Lifesciences Limited (ASX:ANR) has today undertaken to extend by 12 months the expiry date of 250,000 Options which Anatara issued to the Pork Cooperative Research Centre in 2015.

Read Full Article

Queensland Bauxite Ltd (ASX:QBL) MDL Work Programme Approved

🕔9/13/2017 9:34:21 AM

The Board of Queensland Bauxite (ASX:QBL) is pleased to announce that the Department of Natural Resources and Mines has now formally approved the work programme intended under the MDL.

Read Full Article

Regeneus Ltd (ASX:RGS) Edison Investment Report Issued

🕔9/11/2017 7:52:04 AM

The following investment report by Edison titled 'Preparing for a clinical licence deal in Japan' has been published.

Read Full Article

Queensland Bauxite Ltd (ASX:QBL) Approval of Environmental Authority for the MDL Work Program

🕔9/8/2017 3:43:21 PM

The Board of Queensland Bauxite (ASX:QBL) is delighted to announce that Mineral Development License approval has been progressed for the South Johnstone Bauxite Project at Camp Creek in Queensland with the important decision received today from the DEHP to approve the amendment to our previous Environmental Authority, to allow for the work programme intended under the MDL.

Read Full Article

Pharmaxis Ltd (ASX:PXS) Boehringer Ingelheim is Initiating Phase IIa Study for the Development of a New Treatment for Diabetic Retinopathy - a Leading Cause of Vision-Loss

🕔9/8/2017 1:38:29 PM

Boehringer Ingelheim and pharmaceutical research company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim is initiating the Phase IIa study ROBIN. This marks the beginning of the clinical development program for BI 1467335 in a second indication targeting a severe diabetes complication. An already ongoing Phase II clinical study program is investigating the compound in NASH.

Read Full Article

Boehringer Ingelheim Initiates Phase IIa Study of Compound Acquired from Pharmaxis Ltd (ASX:PXS) in Debilitating Liver Disease NASH

🕔9/8/2017 12:01:53 PM

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015.

Read Full Article